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The protective effect of methanolic extract of milk thistle seeds and silymarin against cisplatin-induced
renal toxicity in male rats after a single intraperitoneal injection of 3 mg kg
 1 cisplatin were studied.
Over 5 days, cisplatin-treated rats showed tubular necrosis and elevation in blood urea nitrogen
(BUN) and serum creatinine (Scr). Pretreatment of animals with silymarin (50 mg kg
 1) or extract
(0.6 g kg
 1) 2 h before cisplatin prevented the tubular damage. Rats treated with silymarin or extract
2 h after cisplatin had BUN and Scr significantly lower than those receiving cisplatin, but mild to mod-
erate necrosis was observed. These results suggested that milk thistle may protect against cisplatin-
induced renal toxicity and might serve as a novel combination agent with cisplatin to limit renal injury.
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Introduction
Cisplatin is a potent anticancer agent against solid tumors of
the testes, ovaries, breasts, lungs, bladder, etc. However, in
practice, the use of cisplatin is limited by its marked renal
toxicity (1–4). It has been suggested that the generation of
reactive oxygen species and lipid peroxidation is responsible
for the cisplatin-induced renal tubular injury (5–7).
Flavonoids are naturally occurring substances that possess
various pharmacological actions and therapeutic applications.
Some due to their phenolic structures have antioxidant effect
and inhibit free radical-mediated processes (8–11). Silymarin,
a mixture of three isomeric flavonolignans, is isolated from
milk thistle (Silybum marianum) seeds. Silymarin is used clin-
ically to treat chronic inflammatory liver disease and hepatic
cirrhosis. Hepatoprotection can be attributed to its antioxidant
properties by scavenging free radicals and increasing intracel-
lular concentration of glutathione (12,13).
The aim of this study was to evaluate the protective effect of
milk thistle methanolic extract and silymarin against cisplatin-
induced acute renal failure in rats.
Materials and Methods
Animals
The study was performed on male wistar rats, 8–10 weeks,
200–240 g that were bred and kept at the animal center of
Mashhad School of Pharmacy. They were housed in ventilated
rooms at temperature of 24 ± 2 C with a 12 h light/dark cycle
and 60 ± 5% humidity. They were provided with food and
water ad libitum.
Plant Material
The seeds of milk thistle plant were purchased from local
market of Mashhad and authenticated by matching with the
specimen available in pharmacognosy section of pharmacy
school. A voucher specimen (S/A/102) was also deposited in
the school.
Preparation of Extract
The dried seeds of milk thistle were powdered and 5 g of the
powder was extracted with 95% methanol (100 ml) thrice,
overnight at 28 C with continuous stirring.The pooled extracts
were evaporated under reduced pressure to a known volume.
The residual solvent was evaporated to dryness at 40 Co na
water bath.
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The method is based on the modification of Baliga et al. (14).
Four groups of rats (n ¼ 5) were used to study the effect of
silymarin and methanolic extract on cisplatin-induced renal
toxicity and changes in renal function. Group 1 animals
receivedcisplatin(3mgkg
 1)intraperitoneally.Groups2and3
received intraperitoneal methanolic extract (0.6 g kg
 1)o r
silymarin (50 mg kg
 1; Sigma, UK) 2 h before cisplatin injec-
tion. Groups 4 and 5 received the same dose of extract or sily-
marin 2 h after cisplatin administration. Group 6 acted as
vehicle (normal saline þ 1% w/v methylcellulose) control.
Rats were sacrificed 5 days after cisplatin administration.
The protocols used conformed with guidelines of the conduct
of animal experiments issued by pharmacy school and were
approved by the committee on the ethics of animal experi-
ments in Mashhad University. Blood samples were collected
and analyzed for blood urea nitrogen (BUN) and serum creat-
inine (Scr) by using the commercial kits (15). After bleeding,
the kidneys were removed and fixed in 10% neutral buffered
formalin for at least 24 h. Tissues were processed for micro-





Figure 1. Histological examination. (A) Areas of sever necrosis of proximal tubules, 5 days after injection of 3 mg kg
 1 cisplatin. (B) Minimal tubular necrosis
after treatment with extract (0.6 g kg
 1) 2 h before cisplatin. (C) Minimal tubular necrosis after treatment with silymarin (50 mg kg
 1) 2 h before cisplatin.
(D) Minimal to moderate tubular necrosis after treatment with extract (0.6 g kg
 1) 2 h after cisplatin. (E) Minimal to moderate tubular necrosis after treatment
with silymarin (50 mg kg
 1) 2 h after cisplatin.
384 Cisplatin and silymarinsections were stained with hematoxylin and eosin (16).
The changes seen were limited to the tubulointerstitial areas
andgradedasfollows:grade0,normal;gradeI,areasoftubular
epithelial cell swelling, necrosis and desquamation involving
<25% of cortical tubules; grade II, similar changes involving
>25% but <50% of cortical tubules; grade III, similar changes
involving <50% but <75% of cortical tubules; and grade IV,
similar changes involving >75% of cortical tubules.
Statistical Analysis
The results are expressed as mean ± SEM. Data were analyzed
by one-way analysis of variance. Sequential difference among
mean were calculated at the level of P < 0.05, using Tukey
contrast analysis as needed.
Results and Discussion
The injection of cisplatin produced proximal and distal tubular
necrosis, mainly in the corticomedullary region and intratubu-
lar casts in the outer stripe of the outer medulla (Fig. 1A;
grade IV). Functional nephrotoxicity indices such as BUN
and Scr were elevated in cisplatin-treated rats compared with
saline. Treatment with silymarin or extract 2 h before cisplatin
prevented the increases in BUN and Scr as well as tubular
damage (Fig. 1B and C; grades 0 and I). Rats treated with sily-
marin or extract 2 h after cisplatin had BUN and Scr levels sig-
nificantly lower than those receiving cisplatin alone, but mild
to moderate cell injury was observed (Fig. 1D and E; grades II
and III). The results of renal functional determinations are
summarized in Table 1. Our results are in agreement with
previous study that showed silibinin (200 mg kg
 1, intraven-
ously), one of the component of silymarin, 1 h before the
cisplatin (5 mg kg
 1, intraperitoneally) prevented the effects
of cisplatin on creatinine clearance and proteinuria, and dimin-
ished morphological alteration in proximal tubules (17).
Induction of nephrotoxicity by cisplatin is assumed to be a
rapid process involving reaction with proteins in the renal
tubules (18,19). Because this renal damage occurs within
1 h after administration (20), it is important that the protective
agent is present in renal tissue before damage occurs. This
might explain why complete protection did not result when
silymarin or extract were given after administration of
cisplatin. The acute renal failure indicated by increased Scr
and BUN occurred before the development of tubular necrosis.
These parameters are markers of glomerular filtration rate.
However, it cannot be excluded that the enhancement of these
parameters may be the result of tubular obstruction or tubular
backleak (21). Our finding has been interpreted as a support
of the hypothesis that tubular obstruction and/or tubular fluid
backleak are not involved in the initiation of acute renal failure
in this model of nephrotoxicity.
The mechanisms by which silymarin and extract ameliorate
cisplatin toxicity remains to be elucidated. We supposed they
may inhibit lipid peroxidation by scavenging free radicals
and increasing intracellular concentration of glutathione.
Previous studies have indicated that superoxide anions inactiv-
ate nitric oxide (NO) and that NO-dependent vascular relaxa-
tion is enhanced by superoxide dismutase (22,23). There is a
possibility that they could have maintained RBF as a result
of preserved NO through scavenging of the superoxide anions.
Further studies are needed to determine the exact mechanism
of silymarin and extract.
In conclusion, the present finding suggest that S. marianum
protects against acute cisplatin nephrotoxicity and may be con-
sidered as a potentially useful candidate in the combination
chemotherapy with cisplatin.
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